Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +15.00%
#4 Fabric Protocol Fabric Protocol +11.98%
#5 Bedrock Bedrock +8.56%
#6 Perle Perle +7.51%
#7 BOOK OF MEME BOOK OF MEME +4.97%
#8 Cap Cap +4.16%
#9 Centrifuge Centrifuge +3.80%
#10 Acurast Acurast +3.64%
Coin of the day
EXOD EXOD
Настройки
Язык
Pусский
Валюта
USD
Тема
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Ранг среди акций #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Цена акции
$0.1
Последняя синхронизация: 2024-06-18
Рыночная капитализация
$1.31M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Pascal Biosciences Inc. (PSCBF)

Категория

Healthcare
Выручка компании Pascal Biosciences Inc. (PSCBF)
Выручка на Feb 2024 TTM: $700.83K
Согласно последним финансовым отчетам Pascal Biosciences Inc., текущая выручка компании (TTM) составляет $700.83K. В 2022 году компания получила выручку 0.00 равна выручке в 2021 году, которая составила 0.00. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Pascal Biosciences Inc. с 2019 по 2026
Выручка на конец каждого года
Год Выручка Изменить
2026 (TTM) $700.83K 41.81%
2023 $494.20K 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
Выручка аналогичных компаний или конкурентов
Компания Выручка Разница в выручке Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,801,231.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 859,063.16%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 1,442,584.10%
BE